Clinical research has shown that resorbable scaffolds, or naturally dissolving stents, offer comparable efficacy and safety profile to drug-eluting stents. Specifically, the Absorb naturally dissolving stent has been investigated in single-arm trials and in randomized trials comparing it to a drug-eluting stent (DES). Early and late major adverse cardiac events, revascularizations, and scaffold thromboses have been uncommon and similar to the Xience DES, a market leader in the drug eluting stent category.      Studies in real-world patients are ongoing. 
Catalano et al (2011) evaluated the safety and short-term outcomes of a newly introduced drug-eluting ethmoid stent (the MicroFlow Spacer) in 23 patients with a total of 40 implanted ethmoid sinuses. Patients with medically refractory CRS were treated with patient-appropriate ESS, with the modification of treating the ethmoid sinuses with an ethmoid stent infused with triamcinolone, instead of conventional endoscopic ethmoidectomy. Patients were then followed-up over 6 months. Safety was determined by adverse events. Outcomes were assessed by interval changes in SNOT-20 and Lund-MacKay CT scores. Overall, the pre-operative SNOT-20 mean score was , versus post-operative score of , an improvement of that was both statistically (p < ) and clinically significant. Ethmoid-specific and side-specific Lund-MacKay mean scores both also showed statistically significant improvements. Pre-operative ethmoid-specific Lund-MacKay mean score was , versus post-operative score of , an improvement of (p < ). Pre-operative side-specific Lund-MacKay mean score was , compared with post-operative score of , an improvement of (p < ). There were no significant intra-operative or post-operative complications encountered. The authors concluded that the MicroFlow spacer appeared safe and effective in treating chronic ethmoid sinus disease within the defined follow-up period. They noted that the ability to deliver medication directly to diseased mucosa held wide-ranging potential. The findings of this small study need to be validated by well-designed studies with long-term follow-up.
Dr. Fong has been active as a leader and educator in the field of rhinology. She is an Adjunct Clinical Assistant Professor in the Department of Otolaryngology-Head and Neck Surgery at Stanford University. She has served on the Board of Directors of the American Rhinologic Society (ARS), has chaired the ARS Membership Committee, and has served on the Rhinology and Allergy Education Committee for the American Academy of Otolaryngology. Dr. Fong has authored multiple peer-reviewed publications and speaks nationally on topics related to rhinology and sinusitis. She also participates in multiple clinical research trials related to the field of rhinology.